02/24/21 4:02 PMNasdaq, NYSE : AUPH, AUPAurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational HighlightsAurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) ("Aurinia" or the "Company") today issued its financial results for the fourth quarter and year ended December 31, 2020. Amounts, unless specified otherwise, are expressed in U.S. dollars."Over the past year, Aurinia matured into aRHEA-AIvery positive
02/18/21 6:05 AMNasdaq, NYSE : AUPH, AUPAurinia Pharmaceuticals to Present at the SVB Leerink 10th Annual Global Healthcare ConferenceAurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that members of the executive management team will participate in a fireside chat at the (virtual) SVB Leerink 10 th Annual Global Healthcare Conference on Thursday, February 25, 2021 at 1:00 p.m. ET.In orderRHEA-AIneutral
02/17/21 6:05 AMNasdaq, NYSE : AUPH, AUPAurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that it will release its fourth quarter and year end 2020 financial results on Wednesday, February 24, 2021, after the markets close. Aurinia's management team will host a conference call to discuss the Company'sRHEA-AIneutral
01/22/21 8:24 PMNasdaq, NYSE : AUPH, AUPFDA Approves Aurinia Pharmaceuticals' LUPKYNIS(TM) (voclosporin) for Adult Patients with Active Lupus NephritisAurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) ("Aurinia" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has approved LUPKYNIS TM (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupusRHEA-AIpositive
01/08/21 6:05 AMNasdaq, NYSE : AUPH, AUPAurinia Pharmaceuticals to Present at Two Upcoming Virtual Healthcare ConferencesAurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that members of the management team will participate in two upcoming virtual investor conferences and participate in a panel discussion hosted by Dr. Scott Gottlieb, former FDA Commissioner:H.C. WainwrightRHEA-AIneutral
12/17/20 4:00 AMNasdaq, NYSE : AUPH, AUPAurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and JapanAurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) ("Aurinia" or the "Company") today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of oral voclosporin for the treatment of Lupus Nephritis (LN)RHEA-AIpositive
12/15/20 5:59 PMNasdaq, NYSE : AUPH, AUP, LONNAurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing CapacityAurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) ("Aurinia") and Lonza Ltd. (SIX: LONN) (" Lonza") today announced they have expanded their exclusive manufacturing relationship. The parties entered into a collaborative agreement to build a dedicated manufacturing capacity within Lonza'sRHEA-AIvery positive
12/02/20 6:05 AMNasdaq : AUPHAurinia Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare ConferenceAurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference. Presentations will be available for registered attendees via the Piper Sandler conference site through December 3. In order to listen to the audio webcast, interested parties can register and access the live webcast under "News/Events" through the "Investors" section of the Aurinia coRHEA-AIneutral
11/20/20 5:00 PMNasdaq : AUPHAurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Aurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)RHEA-AIvery positive
11/12/20 4:05 PMNasdaq : AUPHAurinia Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare ConferenceAurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that members of the senior management team will participate in a fireside chat during the 2020 Jefferies Virtual London Healthcare Conference on November 19, 2020 at 11:25 a.m. ET. In order to participate in the audio webcast, interested parties can register and access the live webcast under "News/Events" through the "Investors" section of the Aurinia corporate webRHEA-AIneutral
